Corrigendum: Amino Acids in Cerebrospinal Fluid of Patients With Aneurysmal Subarachnoid Haemorrhage: An Observational Study

A corrigendum on
Amino Acids in Cerebrospinal Fluid of Patients with Aneurysmal Subarachnoid Haemorrhage: An Observational Study

by Sokół, B., Urbaniak, B., Wasik, N., Plewa, S., Klupczynska, A., Jankowski, R., et al. (2017). Front. Neurol. 8:438. doi: 10.3389/fneur.2017.00438

In the original article, there were mistakes in Table 2, Table 3, Table 4, Figure 1, Figure 2, Figure 3 and Figure 4.

In all mentioned tables and figures, quantity of amino acids was described in mM instead of μM. The corrected tables and figures appear below. The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way.

The original article has been updated.

TABLE 2

Table 2. Differences in CSF amino acid level at day 0-3, 5, and 10 post-SAH in healthy individuals (control group) and SAH patients (study group).

TABLE 3

Table 3. Differences in monitored parameters at day 0-3, 5, and 10 post-SAH in patients with good (GO-SAH) and poor (PO-SAH) treatment outcome.

TABLE 4

Table 4. Amino acid level changes in time in good outcome SAH patients with (GO-SAH).

FIGURE 1

Figure 1. Significant differences in monitored parameters on day 0–3 post-SAH between patients with good (GO-SAH) and poor (PO-SAH) treatment outcome. Mann–Whitney test revealed significantly higher levels of: (A) taurine (p = 0.038), (B) aspartic acid (p = 0.038), (C) citruline (p = 0.035), (D) glutamic acid (p = 0.038), (E) 3-methylhistidine (p < 0.01), (F) gamma-aminobutyric acid (p = 0.043), (G) ornithine (p = 0.033), (H) cystathionine (p < 0.01), (I) isoleucine (p = 0.045) in patients with poor outcome. T-Student test revealed significantly higher level of white blood cell count (p < 0.01) in patients with poor outcome (J). In all cases median levels and the 25th and 75th percentile are presented.

FIGURE 2

Figure 2. Significant differences in monitored parameters on day 5 post-SAH between patients with good (GO-SAH) and poor (PO-SAH) treatment outcome. (A) T-Student test revealed significantly higher levels of glutamic acid (p = 0.041) in patients with poor outcome. Mann–Whitney test revealed significantly higher C-reactive protein level (p = 0.020) (B) and white blood cell count (p = 0.044) (C) in patients with poor outcome. In all cases median levels and the 25th and 75th percentile are presented.

FIGURE 3

Figure 3. Significant differences in monitored parameters on day 10 post-SAH between patients with good (GO-SAH) and poor (PO-SAH) treatment outcome. Mann–Whitney test revealed significantly higher 2-aminoadipic acid (p = 0.033) (A) and fibrinogen (p = 0.014) (B) levels in patients with poor outcome. Median levels and the 25th and 75th percentile are presented.

FIGURE 4

Figure 4. Scatter charts showing the correlation between treatment outcome (measured by Glasgow outcome scale at 3 months) and other parameters. Spearman's test revealed significant correlations (cc > 0.6 or cc < −0.6) for: (A) 2-aminoadipic acid on day 10 post-SAH (cc = −0.81), (B,C) cystathionine on day 5 post-SAH (cc = −0.72) and day 10 post-SAH (cc = −0.67), (D) 3-methylhistidine on day 0–3 post-SAH (cc = −0.64), (E) o-phosphoethanolamine on day 10 post-SAH (cc = −0.62), (F) World Federation of Neurosurgical Societies scale (cc = −0.64), (G) Hunt and Hess scale (cc = −0.61), (H) Glasgow coma scale (cc = 0.72), (I,J) C-reactive protein on day 5 post-SAH (cc = −0.64) and day 10 post-SAH (cc = −0.79), (K) Fibrinogen on day 10 post-SAH (cc = −0.97). P-values are <0.05 in all cases.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.